PDS Biotech Receives $4.5M After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program
May 17, 2021 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease...
PDS Biotech Announces Oral Presentation of PDS0101 Data by the National Cancer Institute at 2021 American Society of Clinical Oncology Annual Meeting
April 29, 2021 08:30 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious...
Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting
April 29, 2021 07:30 ET
|
Coherus BioSciences, Inc.
SHANGHAI, China, and REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences,...
Jounce Therapeutics to Present Trial in Progress Posters on the Phase 1 INNATE and the Phase 2 SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
April 28, 2021 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
New data reinforces Immunoscore clinical utility in localized Colon Cancer
October 20, 2020 08:00 ET
|
HalioDx
New data reinforces Immunoscore clinical utility in localized Colon Cancer Changes in patterns of oncology care with the incorporation of immune response in a study of Stage II colon cancer...
Tempus Launches Prospective “Priority” Research Study and Increases Support for Oncology Research Initiatives Despite Pandemic Challenges
June 01, 2020 10:18 ET
|
Tempus
CHICAGO, June 01, 2020 (GLOBE NEWSWIRE) -- Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announces its...
Tempus Launches New Precision Medicine-Driven Tests: Tempus|HRD and Tempus|TO
May 31, 2020 10:30 ET
|
Tempus
CHICAGO, May 31, 2020 (GLOBE NEWSWIRE) -- Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, announced the launch...
Treos Bio Reports Positive Final Results of Phase I/II Off-The-Shelf CRC Cancer Immunotherapy in 2020 ASCO Poster Presentation
May 29, 2020 12:17 ET
|
Treos Bio Corp.
LONDON, May 29, 2020 (GLOBE NEWSWIRE) -- Treos Bio Limited, a clinical stage biopharma company developing precision peptide cancer immunotherapies, today presented positive final data from a Phase...
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ASCO20 Virtual Scientific Program
May 29, 2020 07:37 ET
|
Autolus Therapeutics plc
– Data continue to show encouraging clinical activity alongside tolerable safety to deliver a potentially highly differentiated product profile – Conference call and webcast to be held Monday, June...
SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in Esophagogastric Junction (EGJ), Lung, and Head and Neck Cancers – Late Stage Development Initiated in EGJ Cancer
May 29, 2020 07:30 ET
|
Adaptimmune Therapeutics plc
- New Phase 2 trial in EGJ cancer planned for 1H 2021, after first two patients treated responded to next-generation ADP-A2M4CD8 therapy - - Durability and efficacy data presented at ASCO support...